Alteogen to merge Alteogen Biologics into parent

Alteogen will absorb wholly owned unit Alteogen Biologics, folding clinical, regulatory, marketing functions into a single biopharma operating structure. Merger ratio set at 1 Alteogen share to 0.1679581 shares for each Alteogen Biologics common share held. Alteogen expects 600,477 new common shares to be issued, about 0.86% dilution versus current shares outstanding. Closing targeted for Dec. 29, 2026; new shares slated to list on Jan. 25, 2027.